These findings open up considerable potential for investigating the pharmacological reduction of myostatin in T1DM as an adjuvant therapy that enhances insulin sensitivity and reduces the requirements of exogenous insulin in T1DM persons. The gene discussed is INS; the disease is type 1 diabetes mellitus.